SGCB and hydrops fetalis: Preclinical and clinical evidence supports the potentiation of the nitric oxide (NO)-soluble guanylate cyclase (sGC)-cyclic guanosine monophosphate (cGMP) pathway as a potential therapeutic target in HF.